To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Infliximab (Remicade) Treated Plaque Psoriasis Patients Show Consistently High Clearance in Critical Body Regions: Presented at AAD URL: http://www.pslgroup.com/dg/21C70A.htm Doctor's Guide February 4, 2008
By Bruce Sylvester SAN ANTONIO, TX -- February 4, 2008 -- Researchers report that patients with moderate to severe plaque psoriasis receiving infliximab (Remicade®) achieved a consistently high level of skin clearance in each of the head, trunk, lower and upper extremities. The findings were presented here on February 2 at the American Academy of Dermatology 66th Annual Meeting (AAD). "We found that treatment with infliximab led to a high level of clinical response in each quadrant of the body, said lead investigator Alan Menter, MD, Dermatologist, Baylor Research Institute, Dallas, Texas, United States. Dr. Menter's analysis included 1,462 subjects from three trials: Study of Psoriasis with Infliximab Induction Therapy (SPIRIT); European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS); and Evaluation of Infliximab for Psoriasis in an Efficacy and Safety Study (EXPRESS II). The investigators reported that 70.6 % of subjects receiving infliximab 3 mg/kg and 79.3% of subjects receiving infliximab 5 mg/kg achieved a 75% reduction in Psoriasis Area Severity Index (PASI) score compared with 2.7% of the subjects receiving placebo (both P <.001). Among patients receiving infliximab 3 mg/kg and 5 mg/kg, 39.1% and 52%, respectively, achieved a 90% reduction in PASI compared with 0.1% of patients receiving placebo (both P <.001). Also, a high proportion of infliximab-treated patients achieved highly significant improvements in head and neck-related psoriasis, trunk psoriasis and psoriasis of the lower and upper extremities, compared with the placebo group. At week 10, the proportions of patients achieving at least a 75% or at least a 90% improvement, respectively, in head and neck-related psoriasis in the combined infliximab groups versus placebo in each trial were: SPIRIT, 85.5% versus 22.0% (>= 75%), and 68.9% versus 12.0% (>= 90%); EXPRESS, 84.8% versus 12.5% (>= 75%), and 73.1% versus 8.3% (>= 90%); EXPRESS II, 79.0% versus 10.0% (>= 75%), and 66.6% versus 5.5% (>= 90%). For trunk psoriasis, responses according to PASI score (combined infliximab groups versus placebo; >= 75% and >= 90% improvement, respectively) were: SPIRIT (85.7% vs 11.8%, and 65.8% vs 3.9%); EXPRESS (86.5% vs 5.3%, and 71.7% vs 1.3%); EXPRESS II (79.4% vs 6.8%, and 58.7% vs 4.4%). Scores at week 10 for the upper and lower extremities showed similar improvements. For the upper extremities the proportions achieving >= 75% and >= 90% improvement in scores were: SPIRIT (76.8% vs 5.9% and 48.5% vs 2.4 %); EXPRESS (81.7% vs 3.9% and 56.1% vs 1.3 %), and EXPRESS II (72.4% vs 2.4%, and 45.8% vs 0.5%). For the lower extremities the proportions achieving >= 75% and >= 90% results were: SPIRIT (72.2% vs 7.8% and 48.5% vs 2.0 %); EXPRESS (74.8% vs 2.6%, and 49.5% vs 1.3%); EXPRESS II (64.8% vs 3.8%, and 35.1% vs 0.5%). "We were pleased to see that the results for each quadrant were consistent with the overall improvements that these patients achieved," Dr. Menter added. Funding for the study was provided by Centocor Research and Development and Schering Plough Corporation. [Presentation title: Consistency of Infliximab Response in Different Body Regions for Treatment of Moderate to Severe Psoriasis: Results From Controlled Clinical Trials. Abstract P2607] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.